Prognostic factors in the so-called malignant mesenchymoma: A clinicopathological and immunohistochemical analysis

Toshisada Adachi, O. D.A. Yoshinao, Akio Sakamoto, Takahiro Terashi, Sadafumi Tamiya, Yoichi Hachitanda, Masazumi Tsuneyoshi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The term 'malignant mesenchymoma' (MM) has traditionally been applied to a group of malignant soft tissue tumors that are characterized by the presence of two or more different mesenchymal tissue components in the same neoplasm. Currently, sarcomas with multilineage differentiation fulfilling the criteria of MM tend to be diagnosed as specific sarcomas with heterologous differentiation (e.g., dedifferentiated liposarcoma) rather than MM; however, some cases of these tumors are difficult to classify. The purpose of this study was to analyze the clinicopathological and immunohistochemical features of these unclassifiable tumors, the so-called MM, and to determine whether some parameters are a useful adjunct for the classification of these tumors from the viewpoint of clinical outcome. Twelve cases of so-called MM were investigated retrospectively. The patients (six male, six female) ranged in age from 6 to 71 years (mean 48 years). Tumor size ranged from 3 to 20 cm (mean 13 cm). Tumor locations included the retroperitoneum (five cases), abdominal wall (two), thigh (two), forearm (one), lung (one), and parotid gland (one). The differentiated mesenchymal components were rhabdomyosarcomatous (RMS) (six cases), liposarcomatous (five), chondrosarcomatous (five), osteosarcomatous (five), or leiomyosarcomatous (four). Follow-up in all cases (range 4-129 months; mean 36 months) showed a 67% local recurrence rate, a 33% metastatic rate, and a 50% disease-related mortality. The patients who were under 40 years of age or who had an RMS component showed significantly worse survival than did patients in the other groups. The other mesenchymal components showed no significant correlation with survival. The immunophenotypes of p53 and mdm2 were almost identical between the two mesenchymal components in each case; however, there was no significant correlation between either of these immunophenotypes and the clinical outcome. None of the other factors (gender, tumor site, tumor size, or MIB-1-labeling index) was found to be a statistically significant prognostic indicator. In conclusion, a patient age under 40 years and the presence of an RMS component appear to be poor prognostic indicators of survival in patients with so-called MM, and to be a useful adjunct for the classification of these tumors.

Original languageEnglish
Pages (from-to)803-811
Number of pages9
JournalOncology reports
Volume10
Issue number4
Publication statusPublished - Jul 1 2003

Fingerprint

Neoplasms
Sarcoma
Survival
Malignant mesenchymal tumor
Liposarcoma
Parotid Gland
Abdominal Wall
Thigh
Forearm
Recurrence
Lung
Mortality

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Adachi, T., Yoshinao, O. D. A., Sakamoto, A., Terashi, T., Tamiya, S., Hachitanda, Y., & Tsuneyoshi, M. (2003). Prognostic factors in the so-called malignant mesenchymoma: A clinicopathological and immunohistochemical analysis. Oncology reports, 10(4), 803-811.

Prognostic factors in the so-called malignant mesenchymoma : A clinicopathological and immunohistochemical analysis. / Adachi, Toshisada; Yoshinao, O. D.A.; Sakamoto, Akio; Terashi, Takahiro; Tamiya, Sadafumi; Hachitanda, Yoichi; Tsuneyoshi, Masazumi.

In: Oncology reports, Vol. 10, No. 4, 01.07.2003, p. 803-811.

Research output: Contribution to journalArticle

Adachi, T, Yoshinao, ODA, Sakamoto, A, Terashi, T, Tamiya, S, Hachitanda, Y & Tsuneyoshi, M 2003, 'Prognostic factors in the so-called malignant mesenchymoma: A clinicopathological and immunohistochemical analysis', Oncology reports, vol. 10, no. 4, pp. 803-811.
Adachi, Toshisada ; Yoshinao, O. D.A. ; Sakamoto, Akio ; Terashi, Takahiro ; Tamiya, Sadafumi ; Hachitanda, Yoichi ; Tsuneyoshi, Masazumi. / Prognostic factors in the so-called malignant mesenchymoma : A clinicopathological and immunohistochemical analysis. In: Oncology reports. 2003 ; Vol. 10, No. 4. pp. 803-811.
@article{d2dfcaeddb914afd981c302166c055dd,
title = "Prognostic factors in the so-called malignant mesenchymoma: A clinicopathological and immunohistochemical analysis",
abstract = "The term 'malignant mesenchymoma' (MM) has traditionally been applied to a group of malignant soft tissue tumors that are characterized by the presence of two or more different mesenchymal tissue components in the same neoplasm. Currently, sarcomas with multilineage differentiation fulfilling the criteria of MM tend to be diagnosed as specific sarcomas with heterologous differentiation (e.g., dedifferentiated liposarcoma) rather than MM; however, some cases of these tumors are difficult to classify. The purpose of this study was to analyze the clinicopathological and immunohistochemical features of these unclassifiable tumors, the so-called MM, and to determine whether some parameters are a useful adjunct for the classification of these tumors from the viewpoint of clinical outcome. Twelve cases of so-called MM were investigated retrospectively. The patients (six male, six female) ranged in age from 6 to 71 years (mean 48 years). Tumor size ranged from 3 to 20 cm (mean 13 cm). Tumor locations included the retroperitoneum (five cases), abdominal wall (two), thigh (two), forearm (one), lung (one), and parotid gland (one). The differentiated mesenchymal components were rhabdomyosarcomatous (RMS) (six cases), liposarcomatous (five), chondrosarcomatous (five), osteosarcomatous (five), or leiomyosarcomatous (four). Follow-up in all cases (range 4-129 months; mean 36 months) showed a 67{\%} local recurrence rate, a 33{\%} metastatic rate, and a 50{\%} disease-related mortality. The patients who were under 40 years of age or who had an RMS component showed significantly worse survival than did patients in the other groups. The other mesenchymal components showed no significant correlation with survival. The immunophenotypes of p53 and mdm2 were almost identical between the two mesenchymal components in each case; however, there was no significant correlation between either of these immunophenotypes and the clinical outcome. None of the other factors (gender, tumor site, tumor size, or MIB-1-labeling index) was found to be a statistically significant prognostic indicator. In conclusion, a patient age under 40 years and the presence of an RMS component appear to be poor prognostic indicators of survival in patients with so-called MM, and to be a useful adjunct for the classification of these tumors.",
author = "Toshisada Adachi and Yoshinao, {O. D.A.} and Akio Sakamoto and Takahiro Terashi and Sadafumi Tamiya and Yoichi Hachitanda and Masazumi Tsuneyoshi",
year = "2003",
month = "7",
day = "1",
language = "English",
volume = "10",
pages = "803--811",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Prognostic factors in the so-called malignant mesenchymoma

T2 - A clinicopathological and immunohistochemical analysis

AU - Adachi, Toshisada

AU - Yoshinao, O. D.A.

AU - Sakamoto, Akio

AU - Terashi, Takahiro

AU - Tamiya, Sadafumi

AU - Hachitanda, Yoichi

AU - Tsuneyoshi, Masazumi

PY - 2003/7/1

Y1 - 2003/7/1

N2 - The term 'malignant mesenchymoma' (MM) has traditionally been applied to a group of malignant soft tissue tumors that are characterized by the presence of two or more different mesenchymal tissue components in the same neoplasm. Currently, sarcomas with multilineage differentiation fulfilling the criteria of MM tend to be diagnosed as specific sarcomas with heterologous differentiation (e.g., dedifferentiated liposarcoma) rather than MM; however, some cases of these tumors are difficult to classify. The purpose of this study was to analyze the clinicopathological and immunohistochemical features of these unclassifiable tumors, the so-called MM, and to determine whether some parameters are a useful adjunct for the classification of these tumors from the viewpoint of clinical outcome. Twelve cases of so-called MM were investigated retrospectively. The patients (six male, six female) ranged in age from 6 to 71 years (mean 48 years). Tumor size ranged from 3 to 20 cm (mean 13 cm). Tumor locations included the retroperitoneum (five cases), abdominal wall (two), thigh (two), forearm (one), lung (one), and parotid gland (one). The differentiated mesenchymal components were rhabdomyosarcomatous (RMS) (six cases), liposarcomatous (five), chondrosarcomatous (five), osteosarcomatous (five), or leiomyosarcomatous (four). Follow-up in all cases (range 4-129 months; mean 36 months) showed a 67% local recurrence rate, a 33% metastatic rate, and a 50% disease-related mortality. The patients who were under 40 years of age or who had an RMS component showed significantly worse survival than did patients in the other groups. The other mesenchymal components showed no significant correlation with survival. The immunophenotypes of p53 and mdm2 were almost identical between the two mesenchymal components in each case; however, there was no significant correlation between either of these immunophenotypes and the clinical outcome. None of the other factors (gender, tumor site, tumor size, or MIB-1-labeling index) was found to be a statistically significant prognostic indicator. In conclusion, a patient age under 40 years and the presence of an RMS component appear to be poor prognostic indicators of survival in patients with so-called MM, and to be a useful adjunct for the classification of these tumors.

AB - The term 'malignant mesenchymoma' (MM) has traditionally been applied to a group of malignant soft tissue tumors that are characterized by the presence of two or more different mesenchymal tissue components in the same neoplasm. Currently, sarcomas with multilineage differentiation fulfilling the criteria of MM tend to be diagnosed as specific sarcomas with heterologous differentiation (e.g., dedifferentiated liposarcoma) rather than MM; however, some cases of these tumors are difficult to classify. The purpose of this study was to analyze the clinicopathological and immunohistochemical features of these unclassifiable tumors, the so-called MM, and to determine whether some parameters are a useful adjunct for the classification of these tumors from the viewpoint of clinical outcome. Twelve cases of so-called MM were investigated retrospectively. The patients (six male, six female) ranged in age from 6 to 71 years (mean 48 years). Tumor size ranged from 3 to 20 cm (mean 13 cm). Tumor locations included the retroperitoneum (five cases), abdominal wall (two), thigh (two), forearm (one), lung (one), and parotid gland (one). The differentiated mesenchymal components were rhabdomyosarcomatous (RMS) (six cases), liposarcomatous (five), chondrosarcomatous (five), osteosarcomatous (five), or leiomyosarcomatous (four). Follow-up in all cases (range 4-129 months; mean 36 months) showed a 67% local recurrence rate, a 33% metastatic rate, and a 50% disease-related mortality. The patients who were under 40 years of age or who had an RMS component showed significantly worse survival than did patients in the other groups. The other mesenchymal components showed no significant correlation with survival. The immunophenotypes of p53 and mdm2 were almost identical between the two mesenchymal components in each case; however, there was no significant correlation between either of these immunophenotypes and the clinical outcome. None of the other factors (gender, tumor site, tumor size, or MIB-1-labeling index) was found to be a statistically significant prognostic indicator. In conclusion, a patient age under 40 years and the presence of an RMS component appear to be poor prognostic indicators of survival in patients with so-called MM, and to be a useful adjunct for the classification of these tumors.

UR - http://www.scopus.com/inward/record.url?scp=1542787694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542787694&partnerID=8YFLogxK

M3 - Article

C2 - 12792727

AN - SCOPUS:1542787694

VL - 10

SP - 803

EP - 811

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -